Two complementary studies led by researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have demonstrated a new RNA-based therapeutic strategy that effectively targets one of the most difficult-to-treat cancer genes, Kirsten rat sarcoma viral oncogene homolog (KRAS), while stimulating the body’s immune response to fight tumors.
Continue Reading this article here
